- Home
- NRIX vs PHK Comparison
NRIX vs PHK Comparison
Compare NRIX & PHK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- PHK
- Stock Information
- Founded
- NRIX 2009
- PHK 2003
- Country
- NRIX United States
- PHK United States
- Employees
- NRIX N/A
- PHK N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- PHK Finance/Investors Services
- Sector
- NRIX Health Care
- PHK Finance
- Exchange
- NRIX Nasdaq
- PHK Nasdaq
- Market Cap
- NRIX 970.1M
- PHK 814.6M
- IPO Year
- NRIX 2020
- PHK N/A
- Fundamental
- Price
- NRIX $11.64
- PHK $4.83
- Analyst Decision
- NRIX Strong Buy
- PHK
- Analyst Count
- NRIX 16
- PHK 0
- Target Price
- NRIX $29.56
- PHK N/A
- AVG Volume (30 Days)
- NRIX 978.7K
- PHK 491.5K
- Earning Date
- NRIX 07-09-2025
- PHK 01-01-0001
- Dividend Yield
- NRIX N/A
- PHK 12.61%
- EPS Growth
- NRIX N/A
- PHK N/A
- EPS
- NRIX N/A
- PHK N/A
- Revenue
- NRIX $88,381,000.00
- PHK N/A
- Revenue This Year
- NRIX $34.87
- PHK N/A
- Revenue Next Year
- NRIX N/A
- PHK N/A
- P/E Ratio
- NRIX N/A
- PHK N/A
- Revenue Growth
- NRIX 41.86
- PHK N/A
- 52 Week Low
- NRIX $8.18
- PHK $4.13
- 52 Week High
- NRIX $29.56
- PHK $5.15
- Technical
- Relative Strength Index (RSI)
- NRIX 46.20
- PHK 58.93
- Support Level
- NRIX $11.13
- PHK $4.76
- Resistance Level
- NRIX $11.92
- PHK $4.85
- Average True Range (ATR)
- NRIX 0.77
- PHK 0.03
- MACD
- NRIX -0.15
- PHK 0.00
- Stochastic Oscillator
- NRIX 11.79
- PHK 77.78
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.